AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 152 min read$LLY

Eli Lilly To Showcase Retatrutide, Foundayo & EloraTZP Data At EASD 2026

Eli Lilly (LLY) will present Phase 3 data for retatrutide and Foundayo, and Phase 2 data for eloraTZP at EASD 2026. Retatrutide showed 22.5 kg weight loss and 1.6% A1C reduction. Foundayo demonstrated cardiovascular benefits. LLY also partnered with QurCan for genetic medicine programs.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly To Showcase Retatrutide, Foundayo & EloraTZP Data At EASD 2026 — source image
Source · rttnews.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The upcoming data could reshape market expectations for weight‑loss drugs and influence pricing power.

02

Market read

First‑time pivotal data for retatrutide and Foundayo are likely to move LLY stock and affect the GLP‑1/obesity sector.

03

What to watch

Regulatory timelines and reimbursement uncertainty for triple‑agonist combos could delay commercial impact.

Relevance 8/10Novelty 8/10Timing: pre‑conference data release (EASD 2026, Sep 30)

Background

Eli Lilly's cardiometabolic pipeline includes oral GLP‑1, dual/triple hormone agonists, and amylin‑based combos, positioning it as a leader in obesity and diabetes treatment.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly will present first‑time Phase 3 retatrutide and Phase 3 Foundayo data, plus Phase 2 eloraTZP results at the EASD 2026 conference.

Expected impact

Potential 3‑5% upside ahead of the conference, with volatility on the day of the presentations.

Evidence & confidence

Phase 3 weight‑loss and cardiovascular outcomes are material catalysts; investors typically react strongly to first‑time pivotal data.

Market effects

Sector

Strengthens the broader GLP‑1/obesity drug sector and may pressure peers such as Novo Nordisk and Pfizer.

Regional

Positive for US biotech and pharma equities, especially those with obesity pipelines.

Global

Highlights continued innovation in cardiometabolic therapies worldwide.

Counterpoint

What could challenge this read

If the data fall short of expectations, the stock could face a sharp correction given the high valuation.

Key entities

  • company
    Eli Lilly and Company

    US‑listed pharmaceutical company (ticker LLY) presenting new trial data.

  • company
    QurCan Therapeutics

    Partner in a genetic‑medicine collaboration with Lilly.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 15
$LLYMed

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

Eli Lilly (LLY) reports its oral obesity drug Foundayo has captured over 30% of new U.S. patients starting oral weight-loss medicines, competing against Novo Nordisk's Wegovy. Foundayo, launched in April 2026, costs $149/month for self-pay patients. Lilly's incretin franchise, including Mounjaro and Zepbound, accounted for 65% of its revenue in H1 2026. The U.S. obesity-drug market is projected to exceed $100B annually by 2030, with oral treatments potentially making up over one-third of GLP-1 u

yahoo.com2 min
SEP 15
$LLYHigh

Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says

Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.

cnbc.com2 min
SEP 15
$LLYMedAI 8/10

Eli Lilly Vs. Merck: One is a No

Eli Lilly (LLY) reported Q2 revenue of $23B, up 48% YoY, driven by Mounjaro and Zepbound. Merck (MRK) saw 5% growth to $16.6B, with KEYTRUDA nearing peak penetration. Lilly raised FY2026 guidance to $85-87B and boasts an 86% gross margin. Merck's strategy focuses on new drugs like Lipvendra and WINREVAIR.

aol.com3 min
SEP 15
$LLYHighAI 8/10

Berenberg bullish on Eli Lilly, sees nearly 25% upside

Berenberg upgraded Eli Lilly (LLY) to 'buy' with a $1,400 price target, citing 25% upside potential. Analyst Kerry Holford praised Lilly's leadership in obesity and diabetes markets, strong R&D returns, and diverse pipeline investments, including recent acquisitions. The stock trades at a premium valuation, justified by superior growth and research productivity, according to the analyst.

investing.com2 min
SEP 15
$LLYMedAI 8/10

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Eli Lilly (LLY) will present new data on its cardiometabolic drugs at EASD 2026. Retatrutide showed 20.8% weight loss and 1.6% A1C reduction in TRIUMPH-2. Foundayo (orforglipron) demonstrated cardiovascular benefits in ACHIEVE-4. Lilly will also share Phase 2 data for eloraTZP, a combination of eloralintide and tirzepatide.

prnewswire.com2 min